UnknownNot Applicable

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

China70 participantsStarted 2020-03-24

Plain-language summary

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * RET Fusion Positive * First Diagnosis and Treatment * Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody Exclusion Criteria: * \- Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women

What they're measuring

PFS

Timeframe: may 2020- may 2021 (1 year)

Trial details

NCT IDNCT04322591

SponsorHunan Province Tumor Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-24

Contact for this trial

Yongchang Zhang, MD

+8613873123436 zhangyongchang@csu.edu.cn

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials